RU2157242C1 - Medical membrane-controllable bandage - Google Patents

Abstract

FIELD: medical engineering. SUBSTANCE: device has closed reservoir from semipermeable membrane with pore diameters not less than 2.5 nm, containing xerogel from hydrophilic polymers having molecular mass not less than 14000 Dalton. The bandage has medical preparations of special action kind. EFFECT: low weight; long storage life; enhanced effectiveness in coalescing wounds. 5 dwg

Description

 The invention relates to medicine, in particular surgery, and is a dressing intended for the treatment of purulent wounds, burn surfaces, and a tool that increases the efficiency of engraftment of skin flaps with skin plastic.

 Known dressings made of tissue material, impregnated with drugs [1].

 However, these dressings are sorption, absorb wound, adhere to the surface of the wound. Repeated dressings cause additional injury to the wound, painful.

 Known membrane-controlled drug-distribution systems designed for the local administration of medications directed action, based on the therapeutic situation [2]; [3]; [4]; [5]; [6]; [7].

 However, the function of such devices is the local provision of the tissue region with targeted drugs based on the therapeutic situation.

 A known method of treating wounds using dressings in the form of closed containers of a semipermeable membrane with a pore diameter of 2.5-3.0 nm, in which a solution is changed containing directed drugs and high molecular weight hydrophilic compounds with a molecular weight of at least 14,000 daltons, forming an osmotic pressure in the range of 0.9 to 8.0 mOsmol [8]; [nine]; [ten]; [eleven].

 However, the storage of medicines in aqueous solutions is limited in time, water in dosage forms forms an increased weight, it is difficult to use liquid dialysis dressings in camp conditions.

 The aim of the invention is a medical dressing with reduced weight, increased shelf life, with the effectiveness of wound healing.

 The goal is achieved due to the fact that the dressing is formed in the form of a closed container of a semipermeable membrane with a pore diameter of at least 2.5 nm, containing a xerogel made of hydrophilic polymers with a molecular weight of at least 14,000 daltons, in which there are directional medicines and electrolytes of blood plasma.

Specific implementation examples
A semi-permeable membrane is made of a standard shell OST 49-101-82 "Shell of a cellulose film (cellophane)" 01.01.83, 01.01.88, made in the form of a tube having an outer diameter of 20 mm

 Preparation of a flat xerogel membrane dressing (Fig. 1).

 One end of the tube (1) is tied. The membrane cavity is filled with a gel (2) containing directed medicines and basic electrolytes balanced with a wet plasma. The second end of the membrane tube (3) filled with gel is tied. It turns out a closed membrane cavity filled with a gel solution.

 The membrane container containing the gel is dried by removing water through a semipermeable membrane to a constant weight (Fig. 2).

 As a result of water removal, a flat plate of dry gel (5) (xerogel) is obtained, which contains directional medicines, the main electrolytes of blood plasma and is surrounded by a semipermeable membrane (6).

The use of a flat xerogel membrane-controlled dressing (Fig. 3)
In the presence of an open wound or burn surface (8), a flat xerogel membrane-controlling dressing (7) is applied to the surface of the wound (8) and fixed on it by any available means (9).

 The adsorption of liquid fractions of the wound discharge by a membrane-controlled dressing through a semi-permeable membrane transfers the band xerogel into gel. At the same time, medicines and electrolytes of the rehydrated gel provide the wound with local drug exposure, the gel, absorbing water from the wound tissues, helps to relieve swelling and absorption of low molecular weight biodegradation products. Moreover, due to the properties of the semipermeable membrane, large-molecular components and cellular structures of the wound discharge are preserved in the wound.

 In the case of small exudation on the surface of the wound, the conversion of the xerogel of the dressing into a gel is possible by additionally supplying liquid to the surface or into the cavity of the xerogel membrane-controlling dressing.

Preparation of a tubular xerogel membrane-controlled dressing
If it is necessary to treat inflammatory processes in the hollow organ, it may be necessary to conduct treatment while maintaining the patency of the hollow organ. In this case, the xerogel membrane-controlled dressing can be modified (figure 4).

 For this, the tube (catheter) (10) is wrapped outside with a semipermeable membrane (11) with the formation of a closed cavity (12) for the gel (xerogel) between the walls of the catheter (13) and the semipermeable membrane (14). Removing moisture from the gel by evaporation through the wall of a semipermeable membrane, the gel dressings are transferred to xerogel.

The use of a tubular xerogel membrane-control dressing (Fig. 5)
To treat the walls of a hollow organ, a tubular xerogel membrane-control dressing is introduced into the lumen of the organ (15) (16). By adsorbing fluid from surrounding tissues or by additionally supplying fluid to the dressing cavity, the xerogel is converted into a gel and converted into a medication-dispensing device capable of adsorbing low molecular weight biodegradation products while preserving cell structures and large molecular weight biopolymers of the wound detachable walls of the hollow organ. The presence of a semipermeable membrane in this case keeps the therapeutically active effect at the walls of the hollow organ, and at the same time its patency is not impaired.

 Hydrophilic polymers were used to form the xerogel, in particular polyvinylpyrrolidone with a molecular weight of 14,000 daltons and polyvinylpyrrolidone with a molecular weight of 2,000,000 daltons. The gel was prepared on electrolyte solutions balanced by basic plasma electrolytes.

 From targeted medicines, antibiotics (gentamicin) and local anesthetics (novocaine) were added to the gel. If necessary, based on the therapeutic situation, any medications compatible with the gel components and molecular weights up to 1200 daltons can be added to the gel.

List of references
1. Theory and practice of treating burns: Per. from English / Rudovsky V., Nazilovsky V., Zitkevich V., Zinkevich K. - M .: Medicine, 1980, p. 122.

 2. A.S. USSR N 602185, class A 61 M 1/14, 1978.

 3. Pat. 3939331 (USA). Process for preparing mediciual dressings / Cioca G. et al. Publ. 02.24.76.

 4. Pat. 1420085 (Engl.). Ocular drug dispensing device and process for making the same / Amold R.K. Publ. 14/06/76.

 5. Pat. 1462958 (Engl.). Biodegradable, implantable drug delivery device process for preparing and using the same / Little A.D. Publ. 01/01/76.

 6. Pat. 4002173 (USA). Diester crosslined polyglucan hydrogels and reticulated sponges thereof / Manninh J.M., Stark C.H. Publ. 11/01/77.

 7. Pat. 4203441 (USA). Osmotically trigged device with gas generating means / Theenwes F. Publ. 05.20.80.

 8. A.C. USSR N 1050679, class A 61 M 17/00, 1983.

 9. A.C. USSR N 1171015, class A 61 M 17/00, 1985.

 10. A.C. USSR N 1360727, class A 61 F 9/00, 1987.

 11. A.C. USSR N 1421312, class A 61 M 17/00, 1989.

Claims (1)

 Therapeutic membrane-controlled dressing, including a semi-permeable membrane, drugs, gel, characterized in that the dressing is formed in the form of a closed cavity with walls of a semi-permeable membrane having a pore diameter of at least 2.5 nm, containing a xerogel of hydrophilic polymers with a molecular weight of at least 14000 daltons, in which there are plasma electrolytes and directional medicines.

Images